BIVI vs ATHA vs SAVA vs NRXP

Analysts rate Cassava Sciences, Inc.

(SAVA) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Cassava Sciences, Inc.

(SAVA) delivered a total return of -64. 6%, compared to -99. 9% for BioVie Inc. (BIVI). Over 10 years, the gap is even starker: SAVA returned -19. 5% versus BIVI's -99. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Athira Pharma, Inc.

(ATHA) is the lower-risk stock at 1. 38β versus Cassava Sciences, Inc. 's 1. 99β — meaning SAVA is approximately 44% more volatile than ATHA relative to the S&P 500. On balance sheet safety, BioVie Inc. (BIVI) carries a lower debt/equity ratio of 2% versus 3% for Athira Pharma, Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: BioVie Inc.

grew EPS 83. 4% year-over-year, compared to 2. 0% for Athira Pharma, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

BioVie Inc.

(BIVI) is the more profitable company, earning 0. 0% net margin versus -23. 4% for NRx Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BIVI leads at 0. 0% versus -1324. 4% for NRXP. At the gross margin level — before operating expenses — NRXP leads at 59. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Athira Pharma, Inc.

(ATHA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Cassava Sciences, Inc. (SAVA) carries a higher beta of 1. 99 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ATHA: -97. 5%, SAVA: -19. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.